2020
The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
Brown M, Zhang W, Yan D, Kenath R, Le L, Wang H, Delitto D, Ostrov D, Robertson K, Liu C, Pham K. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC. PLOS ONE 2020, 15: e0226917. PMID: 31929540, PMCID: PMC6957139, DOI: 10.1371/journal.pone.0226917.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaTypes of cancerDuctal adenocarcinomaSurvivin expressionSurvivin inhibitorClinical response rateNovel survivin inhibitorHalf of patientsElevated survivin expressionLower patient survivalPancreatic tumor microenvironmentPotential therapeutic targetExpression of survivinRole of survivinField of oncologyPancreatic cancer linesImmunotherapeutic approachesPatient survivalUntreated cohortTherapeutic responseInhibitor of survivinTreatment resistancePDAC progressionEffective treatmentTumor cell migration
2011
Survivin inhibition is critical for Bcl‐2 family inhibitor, ABT‐263 to induce apoptosis in liver cancer cells
zhao X, Ogunwobi O, Nelson D, Liu C. Survivin inhibition is critical for Bcl‐2 family inhibitor, ABT‐263 to induce apoptosis in liver cancer cells. The FASEB Journal 2011, 25: 563.13-563.13. DOI: 10.1096/fasebj.25.1_supplement.563.13.Peer-Reviewed Original ResearchYM-155Liver cancer cellsABT-263HCC cellsProtein expressionCancer cellsABT-263 treatmentNormal hepatocytesMechanism of actionHCC cell apoptosisBcl-2 inhibitorsSurvivin protein expressionBcl-2 family inhibitorsHCC managementSignificant apoptotic effectHigh dosesLow dosesSurvivin expressionNovel Bcl-2 inhibitorSurvivin inhibitionSurvivin inhibitorChemotherapeutic alternativesInhibitory effectCell apoptosisSurvivin siRNA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply